PMID- 22160638
OWN - NLM
STAT- MEDLINE
DCOM- 20120622
LR  - 20210503
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 132
IP  - 2
DP  - 2012 Apr
TI  - Comparison of two nomograms to predict pathologic complete responses to 
      neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors 
      need specific predictors.
PG  - 601-7
LID - 10.1007/s10549-011-1897-0 [doi]
AB  - The aim of this study is to compare two published nomograms, the "Institut 
      Gustave Roussy/M.D. Anderson Cancer Center" (IGR/MDACC) and the Colleoni 
      nomograms, in predicting pathologic complete responses (pCR) to preoperative 
      chemotherapy in an independent cohort and to assess the impact of HER2 status. 
      Data from 200 patients with breast carcinoma treated with preoperative 
      chemotherapy were collected. We calculated pCR rate predictions with the two 
      nomograms and compared the predictions with the outcomes. Sixty percent of the 
      patients with HER2-positive tumors received trastuzumab concomitantly with 
      taxanes. Model performances were quantified with respect to discrimination and 
      calibration. In the whole population, the area under the ROC curve (AUC) for the 
      IGR/MDACC nomogram and the Colleoni nomogram were 0.74 and 0.75, respectively. 
      Both of them underestimated the pCR rate (P = 0.026 and 0.0005). When patients 
      treated with trastuzumab were excluded, the AUC were excellent: 0.78 for both 
      nomograms with no significant difference between the predicted and the observed 
      pCR (P = 0.14 and 0.15). When the specific population treated with trastuzumab 
      preoperatively was analyzed, the AUC for the IGR/MDACC nomogram and the Colleoni 
      nomogram were poor, 0.52 and 0.53, respectively. The IGR/MDACC and the Colleoni 
      nomograms were accurate in predicting the probability of pCR after preoperative 
      chemotherapy in the HER2-negative population but did not correctly predict pCR in 
      the HER2-positive patients who received trastuzumab. This suggests that responses 
      to preoperative chemotherapy, including trastuzumab, are biologically driven and 
      that a specific nomogram or predictor for HER2-positive patients has to be 
      developed.
FAU - Frati, Albane
AU  - Frati A
AD  - Department of Obstetrics and Gynecology (Pole GYNORESP), Hopital Tenon, 
      Assistance Publique Hopitaux de Paris, 4 rue de la Chine, 75020 Paris, France.
FAU - Chereau, Elisabeth
AU  - Chereau E
FAU - Coutant, Charles
AU  - Coutant C
FAU - Bezu, Corinne
AU  - Bezu C
FAU - Antoine, Martine
AU  - Antoine M
FAU - Chopier, Jocelyne
AU  - Chopier J
FAU - Darai, Emile
AU  - Darai E
FAU - Uzan, Serge
AU  - Uzan S
FAU - Gligorov, Joseph
AU  - Gligorov J
FAU - Rouzier, Roman
AU  - Rouzier R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111209
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Taxoids)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/chemistry/*drug therapy/pathology/surgery
MH  - Chemotherapy, Adjuvant
MH  - Chi-Square Distribution
MH  - *Decision Support Techniques
MH  - Discriminant Analysis
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Mastectomy
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - *Nomograms
MH  - Paris
MH  - Probability
MH  - ROC Curve
MH  - Receptor, ErbB-2/*analysis
MH  - Taxoids/administration & dosage
MH  - Trastuzumab
MH  - Treatment Outcome
EDAT- 2011/12/14 06:00
MHDA- 2012/06/23 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/09/05 00:00 [received]
PHST- 2011/11/22 00:00 [accepted]
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/06/23 06:00 [medline]
AID - 10.1007/s10549-011-1897-0 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2012 Apr;132(2):601-7. doi: 10.1007/s10549-011-1897-0. 
      Epub 2011 Dec 9.